Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment

NCT ID: NCT06881810

Last Updated: 2025-03-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 98 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-29
• Study Completion Date: 2028-03-31

Brief Summary

Research on schizophrenia spectrum disorders (SSD) patients with social impairment is essential for improving treatment, enhancing the lives of affected individuals, reducing stigma, and advancing our understanding of this complex psychiatric disorder. A clinical trial focusing on the improvement of social skills in SSD has the potential to transform clinical practice and support systems to better meet the needs of those living with SSD. Because of the role of oxytocin in regulating social behaviors and emotions, the investigator hypothesizes that it is beneficial in addressing the social cognition deficits observed in SSD when combined with psychosocial interventions.

Conditions

Schizophrenia Spectrum Disorders (SSD)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Oxytocin

A single dose of 80 I.U. oxytocin in aerosol form (Syntocinon® nasal spray) is administered via 20 puffs 2 times per week intranasally. 1 ml of Syntocinon nasal spray contains 40 I.U. of oxytocin, with one puff equivalent to 0.1 ml of nasal spray (4 I.U. per spray). To reach the dose of 80 I.U. a total of ten spray puffs per nostril are required (1 ml per Nostril, 2 ml in total). The nasal spray is applied in a sitting position:

• dose: 80 I.U. = 2 ml Syntocinon® nasal spray (cumulative total dose) is administered as intranasal spray twice a week, 45-75 min. before psychosocial intervention twice a week
• duration of treatment: 12 weeks

Group Type: EXPERIMENTAL

Oxytocin nasal spray

Intervention Type: DRUG

Syntocinon® nasal spray is applied according to description in arms section

Placebo

• 2ml placebo dose is administered twice a week, 45-75 min. before psychosocial intervention twice a week
• duration of treatment: 12 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo nasal spray is applied according to description in arms section

Interventions

Oxytocin nasal spray

Syntocinon® nasal spray is applied according to description in arms section

Intervention Type: DRUG

Placebo

Placebo nasal spray is applied according to description in arms section

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age 18 to 64 years

2. Written informed consent (must be available before enrolment in the clinical trial)

3. ICD-11 diagnosis of schizophrenia or other primary psychotic disorders (6A20-6A25) confirmed by the MINI-DIPS-OA Interview

4. At least one symptom of moderate severity or worse in the PANSS negative subscale (a score ≥ 4 for one or more symptoms from N1-N7 at baseline).

5. In- or outpatient psychosocial treatment on a regular basis at least twice a week during the study

6. Male participants and female participants who are not capable of bearing children or female patients of childbearing potential who use a highly effective birth control method that is medically approved by the health authority at screening.

1. Age 18 to 64 years 2. Written informed consent (must be available before enrolment in the clinical trial) 3. ICD-11 diagnosis of schizophrenia or other primary psychotic disorders (6A20-6A25) confirmed by the MINI-DIPS-OA Interview 4. At least one symptom of moderate severity or worse in the PANSS negative subscale (a score ≥ 4 for one or more symptoms from N1-N7 at baseline). 5. In- or outpatient psychosocial treatment on a regular basis at least twice a week during the study 6. Male participants and female participants who are not capable of bearing children or female patients of childbearing potential who use a highly effective birth control method that is medically approved by the health authority at screening.

Exclusion Criteria

1. Patients who are not suitable for the study in the opinion of the investigator (including acutely suicidal patients)

2. Coercive treatment at the time of study inclusion

3. Diagnosis of primary substance dependency other than nicotine: exclusion alcohol dependency via AUDIT-screening (Bohn, Babor et al. 1995; Babor et al. 2001) and ICD- 11 criteria (MINI-DIPS-OA); exclusion of other drug dependencies other than alcohol and nicotine: drug screening of urine and ICD-11 criteria (MINI-interview: patient fulfilling early (> 3 months) or sustained (>12 months) remission criteria and/or with low severity of substance use disorder according to MINI (ICD-11) are eligible for the study).

4. Documented intolerance to the study drug or any of its ingredients.

5. Pregnancy (incl. positive urine or blood pregnancy test) / breastfeeding (female patients) or lactating individuals

6. Severe endocrinological disorder besides diabetes

7. Endometriosis

8. Concurrent participation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Central Institute of Mental Health, Mannheim

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dusan Hirjak, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Central Institute of Mental Health

Locations

Central Institute of Mental Health, Department of Psychiatry,

Mannheim, Baden-Wurttemberg, Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Dusan Hirjak, Prof. Dr.

Role: CONTACT

dusan.hirjak@zi-mannheim.de

0621 1703 ext. 2540

Facility Contacts

Dusan Hirjak, Prof. Dr.

Role: primary

dusan.hirjak@zi-mannheim.de

++49 621 1703 ext. 2540

Other Identifiers

2023-509433-40-00

Identifier Type: CTIS

Identifier Source: secondary_id

OXY-APS

Identifier Type: -

Identifier Source: org_study_id